期刊文献+

IL-13Rα2在肿瘤研究中的进展 被引量:2

下载PDF
导出
摘要 近年来对肿瘤的治疗,越来越倾向于靶向治疗。所谓靶向治疗,即是在细胞分子水平上,针对已经明确的致癌位点(该位点可以是肿瘤细胞内部的一个蛋白分子,也可以是一个基因片段)来设计相应的治疗药物,药物进入体内会特异地选择致癌位点来结合发生作用,使肿瘤细胞特异性死亡,而不会波及肿瘤周围的正常组织细胞,所以分子靶向治疗又被称为"生物导弹"。
出处 《南昌大学学报(医学版)》 CAS 2013年第1期87-89,共3页 Journal of Nanchang University:Medical Sciences
基金 江西省教育厅科技项目(GJJ12056)
关键词 IL-13RΑ2 肿瘤 IL-13R
  • 相关文献

参考文献29

  • 1Murata T,Obiri N I, Puri R K. Human ovarian-carcinoma celllines express IL-4 and iL-13 receptors: comparison between IL-4-and IL-13-induced signal transduction[J]. Int J Cancer, 1997,70(2) :230-240.
  • 2Daines M O, Hershey G K. A novel mechanism by which in- terferon-gamman can regulate interleukin(IL)-13 responses. evidence for intracellular stores of I1.-13 receptor alpha-2 and their rapid mobilization by interferon ga/nma[J]. Biol Cherm, 2002,227 (12) : 10387-10393.
  • 3David M, Ford D,Bertoglio J, et al. Induction of the IL-13 re- ceptor-chain by IL-4 and IL-13 in human keratinocytes: in- volvement of STAT6,ERK and p38 MAPKPathways[J]. On- cogene, 2001,20 : 6660-6668.
  • 4Andrews A L,Nasir T,Bucchieri F,et al. IL-13 receptor alpha 2:a regulator of IL-13 and IL-4 signal transduetion in primary human fibroblasts[J]. J Allergy Clin Immunol, 2006,118 : 858- 865.
  • 5Husain S R,Joshi B H,Puri R K. Interleukin,13 receptor as a unique target for anti-gliohlastoma therapy[J]. Int J Cancer, 2001,92(2) : 168-175.
  • 6章剑剑,郑伟明.白细胞介素-13及其受体与恶性肿瘤的关系[J].国外医学(肿瘤学分册),2005,32(10):736-739. 被引量:1
  • 7Wu A H,Low W C. Molecular cloning of the rat IL-13 alpha 2 receptor eDNA and its expression in rat tissues[J]. J Neuroon- col,2002,59 : 99-105.
  • 8何晓璐,石小玉.白介素13受体α2的研究进展[J].实用临床医学(江西),2009,10(1):136-138. 被引量:2
  • 9Fichtner Feigl S, Terabe M, Kitani A, et al. Restoration of tumor immunosurveillance via targeting oflnterleukin-13 re- ceptor-tt2l[J] Cancer Res, 2008,68: 3467-3475.
  • 10Michael O D,Yasuhiro T,Bradley A W,et al. Level of expres sion of IL-13Rtt2 impacts receptor distribution and IL-13 Sig- naling[J]. Immune, 2006,176 7495-7501.

二级参考文献77

  • 1Shirwan H. Chronic Allograft Rejection. Do the Th2 Cells Preferentially Induced by Indirect Alloantigen Recognition Play a Dominant Role? [J].Transplantation, 1999,68 : 715- 726.
  • 2Kawakami K, Kawakami M,Puri R K. IL-13 Receptor-target Cytotoxin Cancer Therapy Leads to Complete Eradication of Tumors with the Aid of Phagocytic Cells in Nude Mice Model of Human Cancer[J]. Immunl,2002,169:7119-7126.
  • 3Devries J E, Zurawski G. Immunoregalatory Properties of IL- 13:its Potential Role in Atopic Disease[J]. Int Arch Allergy Immune, 1995,106 : 17.
  • 4Bai A, Eidelman D H, Hogg J C, et al. Proposed Nomenclature for Quantifying Subdivisions of the Bronchial Wall[J]. Appl Physiol, 1994,77(2) : 1011-1014.
  • 5Donaldson D D, Whitters M J, Fitz L J, et al. The Murine IL- 13receptor Alpha 2 : Molecular Cloning, Characterization, and Comparison with Murine IL-13 Receptor Alphal[J]. Immunol, 1998,161 : 2317-2324.
  • 6Michael O D, Yasuhiro T, Bradley A W,et al. Level of Expression of IL-13Ra2 Impacts Receptor Distribution and IL-13 Signaling[J]. Immunol. 2006,176 : 7495-7501.
  • 7Daines M O, Hershey G K. A Novel Mechanism by which Interferon-gamma can Regulate Interleukin(IL)-13 Responses. Evidence for lntracellular Stores of IL-13 Receptor Alpha 2 and their Rapid Mobilization by Interferon-gamma[J]. Biol Cherm, 2002,22,227 (12) : 10387-1093.
  • 8David M,Ford D,Bertoglio J,et al. Induction of the IL-13 receptor-chain by IL-4 and IL-13 in Human Keratinocytes: Involvement of STAT6, ERK and p38 MAPK Pathways[J]. Oncogene 2001,20 : 6660-6668.
  • 9Mentink K,Cheever A W,Thompson R W,et al. IL-13 Receptor a2 Down-modulates Granulomatous Inflammation and Prolongs Host Survival in Schistosomiasis[J]. Proc Natl Acad Sci USA, 2004,101 : 586-590.
  • 10Yasunaga S,Yuyama N,Arima K,et al. The Negative-feedback Regulation of the IL-13 Signal by the IL-13 Receptor 2 Chain in Bronchial Epithelial Cells[J]. Cytokine, 2003,24 : 293-303.

共引文献6

同被引文献47

  • 1Zarogoulidis P,Yarmus L,Zarogoulidis K. New insights for IL-6 targeted therapy as an adjuvant treatment for non-small-cell lung cancer[J].Ther Deliv,2013,(10):1221-1223.
  • 2Park SY,Kim DJ,Aldohayan A. Immune response after systematic lymph node dissection in lung cancer surgery:changes of interleukin-6 level in serum,pleural lavage fluid,and lung supernatant in a dog model[J].{H}WORLD Journal OF SURGERY Oncol,2013,(01):270.
  • 3Song XY,Zhou SJ,Xiao N. Research on the relationship between serum levels of inflammatory cytokines and non-small cell lung cancer[J].Asian Pac J Cancer Prey,2013,(08):4765-4768.
  • 4Su C,Zhou C,Zhou S. Serum cytokine levels in patients with advanced non-small cell lung cancer:correlation with treatment response and survival[J].{H}MEDICAL ONCOLOGY,2010,(04):1453-1457.
  • 5Yamaguchi T,Yamamoto Y,Yokota S. Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lungcancer patients[J].{H}Japanese Journal of Clinical Oncology,1998,(12):740-744.
  • 6Li C,Li H,Jiang K. TLR4 signaling pathway in mouse Lewis lung cancer cells promotes the expression of TGF-β1 and IL-10 and tumor cells migration[J].{H}Bio-Medical Materials and Engineering,2014,(01):869-875.
  • 7Rybojad P,Jabonka A,Wilczyfska B. Surgery decreases number of cells secreting cytotoxic mediators and increases secretion of interleukin 10 in patients with lung cancer[J].{H}EUROPEAN JOURNAL OF SURGICAL ONCOLOGY,2013,(11):1269-1277.
  • 8Umekawa K,Kimura T,Kudoh S. Plasma RANTES,IL-10,and IL-8 levels in non small-cell lung cancer patients treated with EGFR-TKIs[J].BMC Res Notes,2013,(06):139.
  • 9Sararia M,O'Garra A. The regulation of IL-10 production by immune cells[J].{H}Nature reviews Immunology,2010,(03):170-181.
  • 10Kim ES,Kim MS,Moon A. Transforming growth factor (TGF) betain conjunction with H-ras activation promotes malignant progression of MCF10A breast epithelial cells[J].{H}CYTOKINE,2005,(02):8491.

引证文献2

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部